| Literature DB >> 19697032 |
Vikas Suri1, Subhash Varma, Kiran Joshi, Pankaj Malhotra, Savita Kumari, Sanjay Jain.
Abstract
Intravenous immunoglobulin (IVIg) is emerging as the mainstay in the treatment of many autoimmune diseases, including systemic lupus erythematosus. IVIg has been found to be beneficial in myocarditis due to dermatomyositis/polymyositis, Kawasaki disease, and viral myocarditis in children. We report an 18-year-old man of active lupus with worsening cardiac systolic function who did not respond to pulse methylprednisolone and cyclophosphamide, but subsequently showed an improvement in his cardiac function after IVIg administration.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19697032 DOI: 10.1007/s00296-009-1098-x
Source DB: PubMed Journal: Rheumatol Int ISSN: 0172-8172 Impact factor: 2.631